Comparison of Enoxaparin and Warfarin for Secondary Prevention of Cancer-Associated Stroke

Table 1

Baseline characteristics.

	Enoxaparin	Warfarin
	()	()
Male sex	18 (62.1%)	24 (48.0%)	0.227
Age, years	64 (53–67)	66 (60–72)	0.099
Vascular risk factors
Hypertension	6 (20.7%)	21 (42.0%)	0.054
Diabetes	7 (24.1%)	10 (20.0%)	0.666
Hyperlipidemia	1 (3.4%)	6 (12.0%)	0.252
Current smoker	7 (24.1%)	10 (20.0%)	0.666
Coronary artery disease	1 (3.4%)	1 (2.0%)	>0.999
Laboratory findings on admission
Platelet, ×10^3/μL	149 (89–249)	151 (108–229)	0.955
D-dimer, μg/mL	15.08 (4.34–37.32)	11.35 (2.84–37.25)	0.413
Fibrinogen, mg/dL	377 (294–500)	275 (184–432)	0.062
patterns			0.612
Single vascular territory	5 (17.2%)	11 (22.0%)
Single lesion	2	4
Multiple lesions	3	7
Multiple vascular territories	24 (82.8%)	39 (78.0%)
Prestroke medication
Antiplatelet agents	1 (3.4%)	8 (16.0%)	0.143
Anticoagulants	2 (6.9%)	4 (8.0%)	>0.999
Cancer profiles
Primary cancer type			0.229
Lung	11 (37.9%)	27 (54.0%)
Gastrointestinal	6 (20.7%)	6 (12.0%)
Hepatobiliary	5 (17.2%)	10 (20.0%)
Breast-gynecologic	5 (17.2%)	2 (4.0%)
Other	2 (6.9%)	5 (10.0%)
Systemic metastasis	27 (93.1%)	31 (62.0%)	0.003
Adenocarcinoma	19 (65.5%)	35 (71.4%)	0.585

DWI: diffusion-weighted imaging.